Valeritas Holdings, Inc. Presents Positive CBD h-Patch™ Data at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit
September 12, 2019 at 07:00 am EDT
Share
Valeritas Holdings, Inc. announced positive data from a preclinical pharmacokinetic (PK) study of cannabidiol (CBD) subcutaneous infusion was presented at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston, Massachusetts. Data presented at the Summit showed rapid and robust absorption and distribution of 40mg CBD delivered over 24 hours with the h-Patch technology. CBD was detected within one hour of the start of infusion, followed by prolonged elimination with near steady state levels still detectable 24 hours after completion of h-Patch infusion, or 48 hours in total. These data demonstrated that subcutaneous infusion of CBD of 40mg with the h-Patch provided peak plasma levels on par with published human dose-normalized plasma concentrations from a single oral administration of 300mg CBD. Valeritas h-Patch is a drug delivery technology that can facilitate the simple and effective subcutaneous delivery of injectable medicines to patients across a broad range of therapeutic areas. The Company's V-Go is the first FDA-approved product that utilizes the h-Patchâ„¢ technology. To date, more than 20 million V-Go insulin delivery devices have been sold in the United States.
Valeritas Holdings, Inc. is a United States-based medical technology company. The Company's product, V-Go Wearable Insulin Delivery device (V-Go), is a wearable, basal-bolus insulin delivery device for adult patients requiring insulin that enables patients to administer a continuous preset basal rate of insulin over 24 hours. V-Go is a small wearable and completely disposable insulin delivery device that a patient adheres to his or her skin every 24 hours. V-Go enables patients to closely mimic the body's normal physiologic pattern of insulin delivery throughout the day and to manage their diabetes with insulin without the need to plan a daily routine around multiple daily injections. It has developed V-Go utilizing its h-Patch platform as a patient-focused solution to address insulin therapies. Its h-Patch platform facilitates the subcutaneous delivery of injectable medicines to patients across a range of therapeutic areas.